Robert W. Baird Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price upped by Robert W. Baird from $52.00 to $62.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the stock. CRNX has been the topic of several other research reports. Oppenheimer boosted their price target on […]
More Stories
Fox Co. (NASDAQ:FOX) Short Interest Up 39.1% in September
Fox Co. (NASDAQ:FOX – Get Free Report) was the target of a large increase in short interest in the month...
CVB Financial Corp. (NASDAQ:CVBF) Short Interest Update
CVB Financial Corp. (NASDAQ:CVBF – Get Free Report) saw a significant decline in short interest in September. As of September...
Sabine Royalty Trust (NYSE:SBR) Sees Large Drop in Short Interest
Sabine Royalty Trust (NYSE:SBR – Get Free Report) was the recipient of a large decrease in short interest during the...
bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Update
bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) was the target of a significant drop in short interest during the month...
Short Interest in Camden National Co. (NASDAQ:CAC) Expands By 31.5%
Camden National Co. (NASDAQ:CAC – Get Free Report) was the target of a significant increase in short interest during the...
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI) Short Interest Up 48.8% in September
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI – Get Free Report) saw a large growth in short interest...